BHQ880

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Multiple MyelomaMultiple Myeloma Bone DiseaseRenal InsufficiencySmoldering Multiple Myeloma

Phase 1

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

CompletedNCT00741377

Novartis PharmaceuticalsMultiple Myeloma Bone Disease

Start: 2009-01-31End: 2011-12-31Updated: 2013-02-18

Phase 2

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

CompletedNCT01302886

Novartis PharmaceuticalsSmoldering Multiple Myeloma

Start: 2011-05-31End: 2013-11-30Updated: 2020-12-17

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

CompletedNCT01337752

Novartis PharmaceuticalsMultiple Myeloma, Renal Insufficiency

Start: 2012-01-31End: 2013-05-31Updated: 2020-12-17